Stock Information

• Wedbush Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $10
  Wed, Apr 29, 2026 12:02 PM
• Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates - Slideshow
  Tue, Apr 28, 2026 2:03 PM
• Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
  Tue, Apr 28, 2026 2:01 PM
• Transcript : Aclaris Therapeutics, Inc. - Special Call
  Tue, Apr 28, 2026 1:50 PM
• Aclaris Therapeutics says positive full top line results from Phase 1a clinical trial of ATI-055
  Tue, Apr 28, 2026 7:49 AM
• Aclaris Therapeutics : ATI-052 full SAD/MAD results + ATI-2138 update (44ce59)
  Tue, Apr 28, 2026 7:26 AM
• Aclaris Therapeutics Announces Top Line Results From Its Phase 1a Single And Multiple Ascending Dose Trial Of Its Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 And The Selection Of Lichen Llanus As The lead Indication For Its Selective ITK/JAK3 Inhibitor ATI-2138
  Tue, Apr 28, 2026 6:36 AM
• Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
  Tue, Apr 28, 2026 6:31 AM
• Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026
  Mon, Apr 27, 2026 4:50 PM
• Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026
  Mon, Apr 27, 2026 4:45 PM

Financial data not available